HER2 Inhibitor Development
The human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast cancer, as its overexpression is associated with aggressive tumor growth and poor prognosis. At Alfa Cytology, we are at the forefront of innovative cancer research, with a keen focus on developing cutting-edge HER2 inhibitors for the breast cancer therapy.
Introduction to HER2 Inhibitor for Breast Cancer
The human epidermal growth factor receptor 2 (HER2) is a crucial player in the pathogenesis of breast cancer. This receptor tyrosine kinase is overexpressed in approximately 20% of breast cancer cases, leading to enhanced cell proliferation, survival, and metastasis. HER2-positive breast cancers are typically more aggressive, with a higher risk of recurrence and poorer prognosis compared to HER2-negative subtypes.
Fig. 1 Molecular subtypes of BCs. (Hendrick R. E., et al. 2023)
HER2-targeted Therapy Development for Breast Cancer
Given the central role of HER2 in driving tumor growth and progression, this receptor has emerged as a vital therapeutic target in the treatment of breast cancer. The development of HER2-targeted therapies has revolutionized the management of this disease, improving outcomes for HER2-positive breast cancer.
| Therapy | Therapeutics | Phase |
| Novel Monoclonal Antibodies | MM-302 | |
| Inetetamab | ||
| Bispecific HER-2-Targeted Antibodies | Zanidatamab | |
| MBS301 | ||
| Anbenitamab | ||
| Zenocutuzumab | ||
| Novel Tyrosine Kinase Inhibitors (TKIs) | Poziotinib | |
| DZD1516 | ||
| Novel Antibody–Drug Conjugates (ADCs) | Trastuzumab Duocarmycin (SYD985) | |
| Proteolysis-targeting Chimeras | ORM-5029 | |
| Cell Therapies | CAR-T Cell Therapy | |
| CAR-NK Cell Therapy | ||
| CAR-macrophages Therapy | ||
| Cancer Vaccines | GLSI-100 |
Our Services
At Alfa Cytology, we have dedicated our research and development efforts to advancing the field of HER2 inhibitor therapy for breast cancer. Our team has a deep understanding of the complex mechanisms underlying HER2-positive breast cancer, allowing us to develop innovative and targeted therapeutic strategies.
HER2-Targeted Antibodies Development
- Novel Monoclonal Antibodies Development
- Bispecific HER-2-Targeted Antibodies Development
- Select HER2-targeted Antibody–Drug Conjugates Development
HER2-Targeted Small Molecule Inhibitors Development
- Select HER2-targeted TKIs Development
- Targeted HER2 Protein Degraders Development
HER2-Targeted Cell Therapy Development
- CAR-M Therapy Development
- CAR-NK Therapy Development
- CAR-T Therapy Development
HER2-Targeted Cancer Vaccines Development
- HER2-Targeted Peptide Vaccines Development
- HER2-Targeted Protein-Based Vaccines Development
- HER2-Targeted Cell-Based Vaccines Development
As the field of oncology continues to evolve, Alfa Cytology remains at the forefront of innovative therapy development for breast cancer. Through integrated approaches, cutting-edge preclinical models and biomarker-driven strategies, we are committed to advancing this critical area of cancer research. We are committed to collaborating with industry partners, academic institutions, and healthcare providers to accelerate the clinical advancement of our HER2-targeted therapies. If you are interested in our service, please contact us.
References
- Iacopetta D., Ceramella J., and et al. Targeting Breast Cancer: An Overlook on Current Strategies. Int J Mol Sci. 2023, 24(4): 3643.
- Swain S.M., Shastry M. & Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023, 22, 101–126.